Altimmune Inc expected to post a loss of 32 cents a share - Earnings Preview

Altimmune

08/08/2025 16:26

Altimmune Inc ALT.OQ ALT.O is expected to  show a fall in quarterly revenue when it reports  results on August 12 for the period ending June 30 2025

The Gaithersburg Maryland-based  company is expected to report a 75.0% decrease in revenue to $1.25 thousand from $5 thousand a year ago, according to the mean estimate from 8 analysts, based on LSEG data.

‚ÄčLSEG's mean analyst estimate for Altimmune Inc is for a loss of 32 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ‚Äč

Wall Street's median 12-month price target for Altimmune Inc is $20.00, about 82.4% above its last closing price of $3.52

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč

QUARTER ENDING
STARMINESMARTESTIMATE¬ģ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.37
-0.36
-0.26
Beat
28.4
Dec. 31 2025
-0.34
-0.33
-0.33
Met
-0.8
Sep. 30 2024
-0.38
-0.35
-0.32
Beat
9.6‚Äč
Jun. 30 2024
-0.34
-0.34
-0.35
Missed
-2.6
‚Äč‚ÄčMar. 31 2024
-0.36
-0.37
-0.34
Beat
7.4
Dec. 31 2023
-0.56
-0.43
-0.33
Beat
23.9‚Äč
Sep. 30 2023
-0.41
-0.42
-0.39
Beat
8.1
Jun. 30 2023
-0.45
-0.46
-0.32
Beat
31.1

This summary was machine generated August 8 at 15:26 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)